[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635176":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":48,"collaborators":25,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":25,"overallStatus":73,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine Group","EXPERIMENTAL","The subjects received intranasal dexmedetomidine (100 μg, sprayed equally into both nostrils, two sprays per nostril) 15 minutes before surgery in the preoperative preparation area.",[13],"Drug: Intranasal Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal saline Group","PLACEBO_COMPARATOR","The subjects were given an equal volume of normal saline intranasally, which contained no active ingredient.",[19],"Drug: Normal saline",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Intranasal Dexmedetomidine",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Normal saline",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Min Yan, Doctor","CONTACT","15888210247","zryanmin@zju.edu.cn",[36],{"facility":37,"status":25,"city":38,"state":39,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":25},"2nd Affiliated Hospital, School of Medicine, Zhejiang University, China","Hangzhou","Zhejiang","China","CN",{"type":43,"coordinates":44},"Point",[45,46],120.16142,30.29365,{"lat":46,"lon":45},{"type":49,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100635176","phase-4-use-dexmedetomidine-to-protect-myocardial-injury-evaluation-100635176",false,"NCT07549282","Use Dexmedetomidine To Protect Myocardial Injury Evaluation","Effects of Preoperative Intranasal Dexmedetomidine on Perioperative Myocardial Injury and Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: A Prospective, Randomized Controlled Trial","UDOPIE","Inclusion Criteria:\n\n* 18 years ≤ age ≤ 85 years;\n* Patients scheduled to undergo elective coronary angiography or percutaneous coronary intervention (PCI);\n* Classified as American Society of Anesthesiologists (ASA) physical status I-III (ranging from patients with mild systemic disease to those with more severe systemic disease that limits normal physical activity but who remain able to perform light daily tasks);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Allergy or contraindication to dexmedetomidine, such as severe bradycardia (resting heart rate \\\u003C50 beats\u002Fmin), sick sinus syndrome, second-degree or higher atrioventricular block without a pacemaker;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C35% or New York Heart Association functional class III-IV), cardiogenic shock, or hemodynamically unstable patients;\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) or hypotension (systolic blood pressure \\\u003C90 mmHg);\n* Sleep apnea-hypopnea syndrome or Body Mass Index \\>30 kg\u002Fm²;\n* Use of alpha-2 adrenergic receptor agonists (e.g., clonidine) or antagonists, or tricyclic antidepressants, which may affect the action of the study drug, within 1 month before the procedure;\n* Language, visual, or hearing impairment that may affect cognitive assessment;\n* Hepatic or renal insufficiency (Alanine Aminotransferase\u002FAspartate Aminotransferase\u002FCreatinine \\>3 times the upper limit of normal);\n* Anatomical abnormalities of the nasal cavity affecting intranasal drug administration;\n* Pregnant or breastfeeding women.","ALL","18 Years","85 Years",{"count":62,"type":63},1800,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","The goal of this clinical trial is to learn if preoperative intranasal dexmedetomidine works to reduce perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). It will also learn about the safety of intranasal dexmedetomidine. The main questions it aims to answer are:\n\nDoes preoperative intranasal dexmedetomidine lower the incidence of perioperative myocardial injury and myocardial infarction after PCI? Does intranasal dexmedetomidine cause safety concerns in patients undergoing PCI? Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI.\n\nParticipants will:\n\nReceive either intranasal dexmedetomidine (100 μg) or a placebo (normal saline) 15 minutes before the PCI procedure Undergo blood tests to measure cardiac troponin levels before and after the procedure Be followed for up to 30 days after the procedure to record any heart-related events or side effects",[69,70,71,72],"Coronary Heart Disease","Myocardial Injury","Myocardial Infarction","Dexmedetomidine","NOT_YET_RECRUITING","2026-04-17",{"date":76,"type":77},"2026-04-24","ACTUAL",{"date":79,"type":63},"2026-04",{"date":81,"type":63},"2028-04",{"name":5,"class":6},1]